MedPath

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Phase 4
Completed
Conditions
HIV Infections
Registration Number
NCT00005106
Lead Sponsor
Glaxo Wellcome
Brief Summary

The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.

Detailed Description

Patients are randomized to receive stavudine plus lamivudine plus nelfinavir, Combivir (zidovudine plus lamivudine) plus nelfinavir, or Combivir plus abacavir. Patients are stratified into 2 groups based on their screening plasma HIV-1 RNA: (1) greater than 1,000 up to 100,000 copies/ml or (2) greater than 100,000 up to 200,000 copies/ml. Measurements and evaluations for assessment of body fat composition, virologic and immunologic outcomes, markers of alterations in carbohydrate and lipid metabolism, and safety are performed at Baseline, Weeks 4, 8, 16, 24, and every 12 weeks thereafter until Week 96 or withdrawal. In addition, health-related quality of life and health care resource utilization data are collected at specified treatment visits.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (39)

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Arizona Clinical Research Ctr Inc

🇺🇸

Tucson, Arizona, United States

Longbeach Memorial Med Ctr

🇺🇸

Longbeach, California, United States

Good Samaritan Hosp

🇺🇸

Los Angeles, California, United States

THE Clinic

🇺🇸

Los Angeles, California, United States

AIDS Healthcare Foundation

🇺🇸

Los Angeles, California, United States

Maxine Liggins

🇺🇸

Los Angeles, California, United States

UCLA Care Ctr

🇺🇸

Los Angeles, California, United States

Highland Gen Hosp / San Francisco Gen Hosp

🇺🇸

Oakland, California, United States

San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

Scroll for more (29 remaining)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.